PDCD1 and cancer: The study utilized data from 38 patients with la/mUC who received RC48 monotherapy or in conjunction with PD‐1 inhibitors at the Fifth Affiliated Hospital of Zhengzhou University (n = 15), Henan Cancer Hospital (n = 11), and the First Affiliated Hospital of Zhengzhou University (n = 12).